Global Bioreactors Market Set To Grow To $1.4bn By 2022

07 August 2018
Pharma

Visiongain’ has launched a new pharma report Global Bioreactors Market 2017-2027:
5L-20L, 20L-200L, 200L-1500L, Above 1500L, Single-Use, Glass, Stainless Steel, Lab-Scale, Pilot-Scale, Full-Scale, R&D Departments, Biopharmaceutical Manufacturers, Contract Research Organizations, Other End-Users

The bioreactors market is driven by the increasing use of hybrid technologies, a rise in the rate of adoption of single-use technologies, increasing popularity of single-use bioreactor among biopharmaceutical organizations, and a significant growth in the biologics market. The global bioreactor market is dominated by the single-use bioreactors that hold a major share owing to their high usage in various applications. The main factor driving the increased usage of single-use bioreactors includes low upfront investment cost. There is a high adoption rate of single-use bioreactors owing to reduced capital expenditure costs due to the lower costs of cleaning and sterilizing bioreactors and enhancement of the flexibility in operations during drug manufacturing process.

The lead analyst of the report commented “Asia-Pacific and Rest of the World (RoW) are the emerging bioreactor markets. These regions hold tremendous potential to become the bioreactors market giants in the future. Asia-Pacific countries are estimated to demonstrate tremendous growth for bioreactors owing to the massive expansion of the biopharmaceutical sector in this region.

The rising interest of pharmaceutical organizations to enter the biopharmaceutical market will result in consolidation in the form of strategic alliances between contract manufacturing organizations (CMO’s) and large pharmaceutical/biotechnology organizations. This will result in increased investments and access to cutting-edge manufacturing technologies for CMOs. ”

Leading companies featured in the report include Sartorius AG, Thermo Fisher Scientific, Inc., Merck KGaA, GE Healthcare, Danaher Corporation, Eppendorf AG, Applikon Biotechnology Inc., Solaris Biotech, Bioengineering AG, and Infors HT

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Vaccines Sales market set to grow to $75bn by 2024” says new Visiongain report

Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs. This will also lead to more innovative approaches to vaccine development.

25 June 2019

Read

“Global Inflammatory Bowel Diseases (IBD) Drug Market is estimated to reach $8.6bn by 2024” says new Visiongain report

Revenue growth will be driven by rising incidence and prevalence owing to modern lifestyles and improved awareness and diagnosis.

21 June 2019

Read

“Top 25 Vaccines market set to grow to $41bn by 2024” says new Visiongain report

There is an increasing focus to identify diseases that currently do not have a vaccine.

20 June 2019

Read

“Global Ophthalmic Drugs market set to grow to $33bn by 2024” says new Visiongain report

The market for ophthalmic drugs is a growing one.

17 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever